A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

Each year, 50,000 new lung cancer cases are diagnosed in France, with non–small cell lung cancer (NSCLC ... improves the ability to predict treatment responses. Another key advance concerns ...

NSCLC patients who stopped immunotherapy due to side effects still showed lasting disease control and survival benefits..

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

This is especially important given how much the NSCLC treatment landscape has changed in recent years. “It is absolutely unbelievable how the treatment options have changed in the short 7 years ...

Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III ... with AK117 for first-line HNSCC treatment, compared with pembrolizumab.

Key Phase III Trials in NSCLC : Ivonescimab monotherapy vs ... improving and contributing to the global IO cancer treatment landscape. Breakthrough Bispecifics Enter NRDL, Paving the Way for ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to ...